share_log

Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $3

Benzinga Real-time News ·  Nov 8, 2022 08:28

Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target from $3.5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment